Foresight Group LTD Liability Partnership Genmab A/S Transaction History
Foresight Group LTD Liability Partnership
- $625 Billion
- Q1 2025
A detailed history of Foresight Group LTD Liability Partnership transactions in Genmab A/S stock. As of the latest transaction made, Foresight Group LTD Liability Partnership holds 48,725 shares of GMAB stock, worth $990,579. This represents 1.17% of its overall portfolio holdings.
Number of Shares
48,725Holding current value
$990,579% of portfolio
1.17%Shares
1 transactions
Others Institutions Holding GMAB
# of Institutions
247Shares Held
66.2MCall Options Held
729KPut Options Held
398K-
Alliancebernstein L.P. New York, NY14.7MShares$299 Million0.11% of portfolio
-
Orbis Allan Gray LTD Hamilton, D05.71MShares$116 Million0.8% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$103 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.43MShares$90 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.88MShares$58.6 Million0.45% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $13.4B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...